Table 2. Patient characteristics.

Cohort	Patient	Age/ Sex	Karyotype	Mutations	Status	Prior DNMTi	WBC*	Cycles received	Response	Survival (mos)
1	002	75F	Normal	NRAS	Ref	AZAx7 DACx3	2.5	2	No	2
	003	64F	Complex	TP53	Rel	DACx9	3.4	4	No	3.2
	005	78M	Normal	FLT3-ITD NPM1, SF3B1 WT1	Ref	AZAx12 DACx3	6.2	2	No	2.3
2	006	75F	Complex	ASXL1 IDH2, RUNX1 SRSF2	Ref	AZA x 5	1.4	6	HI	5.4
	007	69M	Normal	ASXL1 FLT3-ITD RUNX1 SRSF2	Ref	DACx3	12.2	7	HI	6.9
	008	89M	del(16)	DNMT3A ETV6 PTPN11 SF3B1	Ref	AZAx37 DACx3	41.8	3	No	2.3
3	012	37F	Complex	CEPBA, TP53	Rel	None	5.9	5	HI	8.3
	013	69M	Normal	ASXL1, IDH2 MPL, U2AF1	Ref	DACx32	34.6	3	No	3.6
	015	70M	Near-tetraploidy, t(3;3)	TP53	Ref	AZAx7	1	17	No	19.2
4	020	87M	Normal	FLT3-ITD NPM1, TET2	Rel	AZAx3	2.3 (HU)	2	No	3.2
	023	73M	Normal	TP53, ASXL1 DNMT3A	Rel	DACx16	1.8	1	Died (sepsis)	1
	025	45F	Complex	EED, SUZ12	Rel	DACx2	18.2	2	No	5.2
	026	73M	Complex	TP53	Ref	DACx2	0.6	2	No	5
	029	78M	t(4;7)	ASXL1, GATA2, TET2 RUNX1	Rel	DACx16	2.0	2	No	2.8
	030	53F	t(3;3), -7	PTPN11 GATA2, ETV6 SF1	Rel	DACx4	48.1 (HU)	1	Died (sepsis)	1
	031	86M	Normal	ASXL1, ZRSR2 STAG2, TET2 NRAS, KRAS ASXL2	Ref	AZAx4	22.6 (HU)	7	No	7.9
5	033	74M	del(5q)	ASXL1, RUNX1 CEPBA SRSF2, TET2	Rel	AZAx9	4	4	No	7.2
	034	63F	inv(1)	NPM1 DNMT3A NRAS	Rel	DACx10	2.3	3	CRi	4.2
	036	63F	Normal	ND	Rel	AZAx?	0.3	1	ND	2.4
6	038	57F	Complex	None	Rel	AZAx6	1.6	2	No	14
	040	55M	Complex	U2AF1, ETV6	Ref	AZAx8	1.0	3	No	6.9
	041	73M	del(20q)	ND	Rel	DACx2	0.4	1	No	2.1
7	042	71M	Normal	NPM1, DNMT3A, FLT3, TET2 KRAS, NRAS	Rel	None	4.2	6	CRi	13.8
	043	55M	t(8;21)	RAD21, TET2 CEBPA	Ref	AZAx9	9.8	2	No	4.2
	USC-004*	53F	Complex	TP53 , NF1	Ref	None	0.23	1	No	3

^*x10⁶/ml Ref=Refractory; Rel=Relapsed; DNMTi=DNA methyltransferase inhibitor; AZA=azacitidine; DAC=decitabine